CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2− Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis

CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2− Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis

(1) Background: This study aimed to conduct a NMA and CEA combined study to compare the effectiveness and cost-effectiveness of different CDK4/6 inhibitors (Abem, Palbo, and Ribo) plus NSAI with placebo plus NSAI in the first-line treatment of postmenopausal women with HR+/HER2− ABC from the perspec...

Full description

Bibliographic Details
Main Authors: Ni Zeng, Jiaqi Han, Zijian Liu, Jinlan He, Kun Tian, Nianyong Chen
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Cancers
Subjects:
cost-effectiveness
network meta-analysis
HR+/HER2− advanced or metastatic breast cancer
CDK4/6 inhibitors
palbociclib
ribociclib
Online Access:https://www.mdpi.com/2072-6694/15/13/3386

Internet

https://www.mdpi.com/2072-6694/15/13/3386

Similar Items